© 2021 MJH Life Sciences and Consultant Live. All rights reserved.
July 21, 2021
Data show while women with GDM wanted to be responsible for their own health, an annual reminder and combined appointments would help to screen for T2D.
July 09, 2021
Data show SGLT2is reduced HHF in patients with both stablished HFrEF and CKD and are likely to also be effective in patients with HFpEF.
July 06, 2021
FDA cites pharmacokinetic comparability considerations remained outstanding, while no clinical deficiencies on efficacy and safety were reported.
July 02, 2021
Marc Bonaca, MD, discusses a new analysis of the VOYAGER PAD trial and implications for patients with diabetes and CLI.
July 01, 2021
Elaine M. Apperson discusses treating diabetes in a pediatric population, including diabetes burnout, the effects of food deserts, and the consequences of COVID-19 on treatment.
June 30, 2021
Data show event rates varied two-fold across regions, with risk reduction of T2D and CKD events across geographic regions without heterogeneity.
Part 2 of a Q&A with Elena Christofides, MD highlighting important discussions surrounding ADA 2021, including semaglutide and obesity treatments as they relate to T2D.
June 29, 2021
In part 1 of a Q&A, Elena Christofides, MD highlights important discussions surrounding ADA 2021, including cardiometabolic medicine and risk factors for T1D.
Investigative ORMD-0701 has potential to regulate the insulin-glucagon balance in patients.
June 28, 2021
Changes in physical activity and diet may be main cause for worsening of diabetes control.